SS-31

Key Findings Beyond Approved Indication

Beyond the BTHS approval basis, the MMPOWER-3 trial provided a critical insight: while the overall PMM population did not meet co-primary endpoints, the pre-specified nuclear-gene PMD (nPMD) subgroup demonstrated a meaningful 6MWT improvement that the mtDNA mutation subgroup did not. This subgroup-driven hypothesis is now the basis for the NuPOWER Phase 3 trial, which is fully enrolled as of May 2026. This represents a precision-medicine evolution in mitochondrial therapeutics — matching therapeutic mechanism to genetically defined subpopulations most likely to respond.

In dry AMD, preclinical rationale is strong: photoreceptors have among the highest mitochondrial density and oxygen consumption of any cell type, and cardiolipin damage in photoreceptor outer segments has been documented in AMD pathology. The ReCLAIM Phase 1/2 studies showed preliminary ellipsoid zone (EZ) preservation signals, and the ReNEW Phase 3 trial uses EZ area loss (measured by spectral domain-OCT) as its primary endpoint — a highly quantifiable structural biomarker with regulatory precedent in retinal disease trials.

U.S. REGULATORY FRAMEWORK — ELAMIPRETIDE (MAY 2026)

NDA Timeline — From Submission to Accelerated Approval

SAFETY PROFILE — ESTABLISHED WARNINGS AND MONITORING

FDA Label Warnings and Adverse Event Data (May 2026)

Elamipretide has a notably clean nonclinical safety profile: the FDA integrated review for NDA 215244 explicitly states ‘no nonclinical safety issues have been identified.’ The primary clinical safety signal is injection site reactions — an expected class effect for daily subcutaneous peptide injections — and rare but labelled hypersensitivity reactions. The absence of the complex multi-organ safety profile seen with systemically active drugs (e.g., GLP-1 receptor agonists) reflects elamipretide’s subcellular specificity — it acts within the IMM rather than through circulating receptor pathways.

U.S. MARKET ANALYSIS AND POSITIONING (MAY 2026)

Mitochondrial Therapeutics Landscape

Elamipretide’s September 2025 accelerated approval establishes it as the founding molecule of an emerging therapeutic category: FDA-approved mitochondria-targeted therapeutics. The Barth syndrome indication is ultra-rare (~150 U.S. patients; ~1:1,000,000 male births), which limits commercial scale in the approved indication but anchors the regulatory and scientific credibility of the platform for broader indications. The orphan drug designation confers 7-year market exclusivity from approval date (through approximately September 2032), along with accelerated approval and RPD priority review voucher (PRV) benefits.

The broader clinical opportunity — heart failure (HFrEF affects ~3 million U.S. patients), dry AMD (~11 million U.S. patients), and PMM (estimated 1:5,000–10,000 prevalence) — represents the commercial upside. NuPOWER (nPMD Phase 3, fully enrolled) and ReNEW (dry AMD Phase 3, ongoing) are the two largest near-term value drivers. If NuPOWER meets its primary endpoint (6MWT improvement in the nPMD subgroup), a supplemental NDA for a substantially larger PMM population becomes viable, with Breakthrough Therapy Designation for dry AMD accelerating the ReNEW path.

RECOMMENDED CONTENT AND DEVELOPMENT STRATEGY (2026)

For U.S. SEO Content Creators and Pharma/Research Professionals

The strongest 2026 U.S. content and development positioning for elamipretide is: anchor to FDA approval, distinguish from RUO peptide category, and build mechanism-first authority. The December 2025 Google core update has penalized thin, RUO-positioned peptide content — elamipretide content that treats SS-31 as a generic research peptide will be de-ranked, while E-E-A-T-compliant, FDA-primary-source-anchored scientific reference content gains visibility.

FREQUENTLY ASKED QUESTIONS — SCIENTIFIC AND REGULATORY REFERENCE

Q1: What is elamipretide’s PubChem identifier and molecular formula?

Elamipretide is registered in PubChem under Compound ID (CID) 11764719, with free-base molecular formula C32H49N9O5 and molecular weight 639.80 g/mol. The pharmaceutical hydrochloride salt form (C32H49N9O5 · 3HCl, MW ~749.2) is defined in the AMA-USAN statement of January 2019. CAS Registry Number for the free base is 736992-21-5; CAS for the HCl salt is 72244098-12-0. IUPHAR/BPS Ligand ID is 14276 (guidetopharmacology.org). DrugBank ID: DB11981. KEGG D10925 (free base) and D11542 (HCl). Synonyms include SS-31, MTP-131, Bendavia, and RX-31. The authoritative compound record is at https://pubchem.ncbi.nlm.nih.gov/compound/11764719.

Q2: What are the four residues and why does the sequence matter?

The sequence D-Arg–Dmt–Lys–Phe–NH2 is not arbitrary — it is an engineered alternating aromatic-cationic motif. D-Arginine at position 1 provides protease resistance (D-configuration resists most endopeptidases) and a +1 cationic charge for cardiolipin electrostatic interaction. 2′,6′- Dimethyltyrosine (Dmt) at position 2 is the critical aromatic-cationic bridge — its dimethyl substitution on the aromatic ring increases aromatic character, reduces tyrosine hydroxyl group reactivity, and is essential for mitochondrial targeting: replacing Dmt with standard Tyr significantly reduces mitochondrial accumulation. L-Lysine at position 3 provides a second +1 charge. L-Phenylalanine amide at position 4 provides the second aromatic moiety and the C-terminal amide that eliminates the carboxyl group’s negative charge, completing the +3 net charge and the alternating structure. No other peptide in clinical development shares this precise architecture.

Q3: What is FORZINITY and what is its FDA status?

FORZINITY (elamipretide HCl injection) received FDA accelerated approval on September 19, 2025 under NDA 215244, sponsored by Stealth BioTherapeutics Inc. (Needham, Massachusetts). It is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. It is the first FDA-approved treatment for Barth syndrome and the first FDA-approved mitochondria-targeted therapeutic. Continued approval is contingent on verification of clinical benefit in a post-marketing confirmatory trial. It is administered as a once-daily subcutaneous injection. Regulatory designations include Orphan Drug, Fast Track, and Rare Pediatric Disease. NDA number: 215244 (not in Purple Book — regulated as a drug under CDER, not as a biologic).

Q4: What is the TAZPOWER trial and how did it support the approval?

TAZPOWER (NCT03098797; SPIBA-201) was a randomized, double-blind, placebo-controlled crossover trial in 12 patients aged ≥12 years, weighing >30 kg, with genetically confirmed Barth syndrome. The primary endpoints — 6MWT distance change and Barth Syndrome Assessment Scale total fatigue — were not met in the 12-week randomized period. However, during the open-label extension (OLE), 8 of the original 12 patients were followed through week 168, demonstrating a median change from baseline in knee extensor muscle strength of +63 Newtons (range 38–78 N). The FDA accepted knee extensor muscle strength as a surrogate endpoint reasonably likely to predict clinical benefit (improved standing ability and ambulation), enabling accelerated approval. The SPIBA-001 natural history control study provided a comparison arm for the efficacy package.

Q5: How does elamipretide differ from typical ‘research peptides’ like BPC-157 or TB-500?

Elamipretide is categorically different from research-use-only (RUO) peptides. BPC-157, TB-500 (thymosin beta-4 fragment), AOD-9604, and similar peptides are sold as RUO compounds with no approved indications, no NDA or BLA, no FDA-reviewed clinical data package, and no manufacturing oversight at commercial scale. Elamipretide has: (1) a USAN-assigned INN (elamipretide hydrochloride, 2019); (2) an FDA-approved NDA (215244) supported by clinical trial data; (3) a trade name (FORZINITY); (4) an approved indication; (5) a manufacturer held to GMP standards; (6) an FDA-reviewed label with safety information; and (7) orphan drug exclusivity. As Eric Topol observed in Ground Truths (The Peptide Craze, 2025), conflating FDA-approved GLP-1 drugs with unregulated peptides misrepresents the regulatory and safety landscape — the same principle applies here to elamipretide vs. RUO SS-31 marketed online.

Q6: What is the compounding status of elamipretide (May 2026)?

Elamipretide is not a legitimate compounding target in the U.S. as of May 2026. It is an FDA-approved drug under NDA 215244. FDA policies on compounding are clear: compounding copies of commercially available approved drug products is generally not permitted under sections 503A and 503B of the FD&C Act unless specific clinical need criteria are met. The analogy to the GLP-1/semaglutide compounding enforcement trajectory is instructive — once a drug achieves NDA approval and commercial supply is established, compounding legitimacy collapses rapidly. Any content, product listing, or business model that frames elamipretide (SS-31) as a freely available RUO peptide for compounding is both factually incorrect and exposed to FDA and FTC enforcement.

Q7: What are the primary safety concerns in the FDA label?

The most common adverse event is mild-to-moderate injection site reactions (erythema, induration, pruritus, pain, bruising, urticaria), expected for a daily subcutaneous injection and typically resolving upon discontinuation. The labelled warning of clinical significance is hypersensitivity reactions — rare but potentially serious, requiring urgent medical attention and potentially permanent discontinuation; no hypersensitivity fatalities have been reported. Headache (~7.3%) and nausea (~3.0%) were the most common systemic adverse events in early-phase studies at IV doses. The nonclinical safety profile is clean: the FDA integrated review for NDA 215244 states no significant nonclinical safety issues were identified.

Q8: What trials are active for elamipretide beyond Barth syndrome (May 2026)?

Three major active programmes: (1) NuPOWER (NCT05162768) — Phase 3, fully enrolled, targeting the nuclear-gene PMD subgroup from MMPOWER-3 that showed meaningful 6MWT improvement; primary endpoint 6MWT change from baseline. (2) ReNEW (NCT05330000) — Phase 3 dry AMD trial, ongoing; primary endpoint rate of change in macular area of photoreceptor loss by spectral domain-OCT ellipsoid zone mapping; Breakthrough Therapy Designation reported. (3) Friedreich’s Ataxia IIS (NCT05168774) — Phase 2 investigator-initiated; ongoing, results pending. Heart failure (PROGRESS follow-on) remains in scientific discussion with no active Phase 3 as of May 2026.

LIMITATIONS, CONTROVERSIES, AND RESEARCH GAPS

Despite accelerated FDA approval and an extensive clinical development history, several limitations and open questions remain in elamipretide research:

1. Accelerated approval basis for Barth syndrome uses knee extensor muscle strength as a surrogate endpoint — clinical meaningfulness confirmed only in the OLE, not the randomized period; confirmatory trial required for full approval.
2. MMPOWER-3 did not meet co-primary endpoints in the overall PMM population — benefits appear limited to the nPMD subgroup; NuPOWER results will be determinative for the PMM indication.
3. PROGRESS-HF Phase 2 did not improve LVESV at 4 weeks in HFrEF — whether longer duration, different endpoints, or patient enrichment strategies could rescue HF programme is unresolved.
4. Small Barth syndrome trial size (TAZPOWER: n=12) limits statistical power and generalizability; ultra-rare disease populations pose fundamental trial design challenges.
5. Long-term safety data beyond 168 weeks (TAZPOWER OLE) is limited; pediatric long-term data is still accumulating under the confirmatory trial requirement.
6. Mechanism of cardiolipin binding — while well-supported, the precise protein-level interactome and whether all observed effects are CL-dependent remains an active research question.
7. PK characterization in the approved label is limited compared to small-molecule drugs; SC bioavailability reported as ~92% in Phase 1 but full PK profiling in special populations (renal, hepatic impairment) is not comprehensively published.
8. Commercial manufacturing at scale for a tetrapeptide with D-amino acid and unusual Dmt residue introduces CMC complexity; no public detailed disclosure of commercial synthesis route or impurity control strategy.
9. RUO SS-31 sold online has no analytical QC, no confirmed purity, no cardiolipin-binding activity verification — and conflation of approved FORZINITY with online SS-31 products creates patient safety and regulatory compliance risks.

REGULATORY AND COMPLIANCE STATEMENT — SCIENTIFIC REFERENCE DOCUMENT

KEY REFERENCES — FDA / PubChem / PubMed / ClinicalTrials.gov VERIFIED

Scientific Reference Document | Educational and Professional Use Only

Elamipretide is an FDA-approved prescription drug (NDA 215244). This document is not a product listing. No clinical use is implied or recommended.